CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) Director Leonard Post sold 1,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $62.06, for a total transaction of $62,060.00. Following the transaction, the director owned 1,000 shares in the company, valued at approximately $62,060. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
CG Oncology Price Performance
Shares of NASDAQ CGON traded up $0.11 during mid-day trading on Monday, hitting $59.96. The company’s stock had a trading volume of 1,215,168 shares, compared to its average volume of 1,094,430. The stock has a market cap of $5.31 billion, a price-to-earnings ratio of -22.29 and a beta of 0.28. CG Oncology, Inc. has a one year low of $35.80 and a one year high of $80.97. The company’s fifty day simple moving average is $72.27 and its 200-day simple moving average is $68.97.
CG Oncology (NASDAQ:CGON – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.36 million. CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%. On average, sell-side analysts predict that CG Oncology, Inc. will post -3.31 EPS for the current year.
Analyst Ratings Changes
CGON has been the subject of several recent research reports. Wall Street Zen cut shares of CG Oncology from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Thursday. Truist Financial upped their price objective on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a report on Friday, August 7th. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of CG Oncology in a research note on Wednesday, July 29th. Finally, Piper Sandler raised their target price on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.50.
Read Our Latest Analysis on CGON
Institutional Trading of CG Oncology
A number of large investors have recently made changes to their positions in CGON. GAMMA Investing LLC increased its holdings in shares of CG Oncology by 47.9% in the third quarter. GAMMA Investing LLC now owns 1,081 shares of the company’s stock worth $77,000 after acquiring an additional 350 shares in the last quarter. Fiduciary Financial Advisors bought a new position in shares of CG Oncology during the 2nd quarter valued at about $28,000. NFSG Corp acquired a new position in shares of CG Oncology in the 1st quarter valued at approximately $34,000. Fifth Third Bancorp acquired a new position in shares of CG Oncology in the 1st quarter valued at approximately $74,000. Finally, KBC Group NV bought a new stake in CG Oncology during the 1st quarter worth approximately $78,000. Institutional investors own 26.56% of the company’s stock.
About CG Oncology
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biotechnology company focused on developing therapies for bladder cancer and other cancers affecting the urinary tract. The company is developing medicines designed to stimulate the immune system and target tumor cells within the bladder.
Its lead product candidate is cretostimogene grenadenorep, an investigational intravesical therapy based on an oncolytic adenovirus. The treatment is designed to be administered directly into the bladder, where it may selectively infect cancer cells, promote their destruction and activate an immune response against the tumor.
Featured Stories
- Five stocks we like better than CG Oncology
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
